Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.
| 1.59 | |
| 1.62 | |
| - | |
| 1.6438 | |
| 1.58 | |
| 1.52-28.2 | |
| 2 596 K | |
| 1 633 K | |
| 0 | |
| -2.46 | |
| 0.216 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Diffusion has a highly engaged and independent board that possesses the right skills and experience to execute the strategic review process Diffusion received bids from more than 15 companies particip...
SAN DIEGO, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the develop...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
